Zacks Investment Research upgraded shares of HTG Molecular Diagnostics (NASDAQ:HTGM) from a hold rating to a buy rating in a research note issued to investors on Wednesday. They currently have $4.00 price target on the medical research company’s stock.

According to Zacks, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. “

Other equities research analysts also recently issued research reports about the stock. Canaccord Genuity boosted their target price on shares of HTG Molecular Diagnostics to $5.00 in a research note on Friday, January 5th. HC Wainwright set a $6.00 price target on shares of HTG Molecular Diagnostics and gave the stock a buy rating in a research report on Friday, January 5th. Finally, ValuEngine upgraded shares of HTG Molecular Diagnostics from a strong sell rating to a sell rating in a research report on Monday, October 23rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. HTG Molecular Diagnostics has a consensus rating of Hold and an average price target of $5.25.

Shares of HTG Molecular Diagnostics (NASDAQ:HTGM) traded down $0.11 during trading hours on Wednesday, hitting $3.29. 6,910,124 shares of the stock traded hands, compared to its average volume of 1,350,000. HTG Molecular Diagnostics has a 52 week low of $1.20 and a 52 week high of $13.25. The firm has a market cap of $36.45 and a P/E ratio of -1.29.

HTG Molecular Diagnostics (NASDAQ:HTGM) last issued its earnings results on Tuesday, November 7th. The medical research company reported ($0.46) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.03. analysts predict that HTG Molecular Diagnostics will post -1.92 EPS for the current year.

A hedge fund recently raised its stake in HTG Molecular Diagnostics stock. Vanguard Group Inc. increased its stake in shares of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) by 38.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 135,234 shares of the medical research company’s stock after buying an additional 37,841 shares during the period. Vanguard Group Inc. owned 1.42% of HTG Molecular Diagnostics worth $359,000 at the end of the most recent quarter. 15.15% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was first published by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.dailypolitical.com/2018/01/20/htg-molecular-diagnostics-htgm-lifted-to-buy-at-zacks-investment-research.html.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Get a free copy of the Zacks research report on HTG Molecular Diagnostics (HTGM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.